These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 5066598)

  • 1. Alterations in circulating estradiol-17-beta in male patients with Graves's disease.
    Chopra IJ; Abraham GE; Chopra U; Solomon DH; Odell WD
    N Engl J Med; 1972 Jan; 286(3):124-9. PubMed ID: 5066598
    [No Abstract]   [Full Text] [Related]  

  • 2. Status of estrogen-androgen balance in hyperthyroid men with Graves' disease.
    Chopra IJ; Tulchinsky D
    J Clin Endocrinol Metab; 1974 Feb; 38(2):269-77. PubMed ID: 4405908
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationships among immunoglobulin markers in Graves' disease.
    Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
    J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of subgroups of euthyroid graves's ophthalmopathy.
    Solomon DH; Chopra IJ; Chopra U; Smith FJ
    N Engl J Med; 1977 Jan; 296(4):181-6. PubMed ID: 576175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
    McKenzie JM; Zakarija M; D'Amour P; Joasoo A
    N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of thyroid stimulating immunoglobulins of Graves's disease in neonatal thyrotoxicosis.
    Munro DS; Dirmikis SM; Humphries H; Smith T; Broadhead GD
    Br J Obstet Gynaecol; 1978 Nov; 85(11):837-43. PubMed ID: 581471
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease.
    Greer MA; Kammer H; Bouma DJ
    N Engl J Med; 1977 Jul; 297(4):173-6. PubMed ID: 69269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 10. Current concepts in management of thyroid disease.
    DeGroot LJ
    Med Clin North Am; 1970 Jan; 54(1):117-30. PubMed ID: 4189143
    [No Abstract]   [Full Text] [Related]  

  • 11. Decreased secretion of gonadotropins in a patient with Graves' disease.
    Hakamata M; Itoh M; Sudo Y; Katada E; Miyata N
    Exp Clin Endocrinol Diabetes; 1996; 104(1):85-8. PubMed ID: 8750576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood levels of gonadotropins and gonadal hormones in gynecomastia associated with chronic hemodialysis.
    Sawin CT; Longcope C; Schmitt GW; Ryan RJ
    J Clin Endocrinol Metab; 1973 May; 36(5):988-90. PubMed ID: 4698251
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional relationships of the hypothalamic-pituitary-testicular system in Graves' disease.
    Földes J; Bános C; Fehér T; Bodrogi L; Szalay F; Borvendég J; Csillag J; Takó J
    Acta Med Acad Sci Hung; 1982; 39(3-4):109-16. PubMed ID: 6821015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Persistent puberal gynecomastia. Diagnosis and treatment].
    Franchella A; Pelizzo G; Nanetti C; De Santis V; Bagni B
    Minerva Chir; 1988 Mar; 43(5):401-5. PubMed ID: 3135515
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent pubertal macromastia.
    Marynick SP; Nisula BC; Pita JC; Loriaux DL
    J Clin Endocrinol Metab; 1980 Jan; 50(1):128-30. PubMed ID: 7188613
    [No Abstract]   [Full Text] [Related]  

  • 16. Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids.
    Berkovitz GD; Guerami A; Brown TR; MacDonald PC; Migeon CJ
    J Clin Invest; 1985 Jun; 75(6):1763-9. PubMed ID: 3924954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of the study of plasma estrogens in the exploration of gynecomastia. Apropos of 48 cases].
    Hugues JN; Modigliani E; Mariel L; Adessi G; Delzant G; Attali JR; Sebaoun J
    Ann Endocrinol (Paris); 1977; 38(3):179-93. PubMed ID: 900876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynaecomastia and raised oestradiol concentrations.
    Vierhapper H; Nowotny P
    Lancet; 1999 Feb; 353(9153):640. PubMed ID: 10030331
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical significance of LATS and TSH in the blood.
    Lemarchand-Béraud T; Griessen M; Scazziga BR
    Ann Clin Res; 1972 Jun; 4(3):121-37. PubMed ID: 4625026
    [No Abstract]   [Full Text] [Related]  

  • 20. The absence of positive feedback between estrogen and luteinizing hormone in sexually immature girls.
    Reiter EO; Kulin HE; Hamwood SM
    Pediatr Res; 1974 Aug; 8(8):740-5. PubMed ID: 4844524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.